Personalis Announces Phase 3 LAURA Trial Data With AstraZeneca Showing NeXT Personal MRD Test Effectively Assesses Post-CRT Response In EGFRm Stage III NSCLC

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (LAURA). The findings demonstrate that Personalis' highly sensitive molecular residual disease (MRD) test, NeXT Personal®, is a useful tool in assessing the maintenance treatment response post-CRT in patients with unresectable stage III, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).

The new LAURA analysis will be presented at the ESMO 2025 Conference in Berlin, Germany, demonstrating key findings for NeXT Personal:

• Treatment monitoring: Osimertinib treatment led to MRD clearance in most patients with post-chemoradiotherapy (post-CRT) MRD, demonstrating the utility of ctDNA for monitoring the maintenance therapy response
• Lead time to progression: NeXT Personal detected MRD progression with a median lead time of 5 months ahead of Blinded Independent Central Review (BICR) assessed disease progression